Published Papers & Misc - FUJII Yasuhisa

21. Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii Y. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology Jinzaki M.Eur Urol Oncol (IF: 2.51; Q1). 2022.08;

22. Miyauchi M, Akashi T, Furukawa A, Uchida K, Tamura T, Ando N, Kirimura S, Shintaku H, Yamamoto K, Ito T, Miura K, Kayamori K, Ariizumi Y, Asakage T, Kudo A, Tanabe M, Fujii Y, Ishibashi H, Okubo K, Murakami M, Yamada T, Takemoto A, Bae Y, Eishi Y, Ohashi K. Endocr Pathol. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma Endocr Pathol. 2022.08; 33 (4): 506-518.

23. Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab Asia Pac J Clin Oncol (IF: 2.6; Q4). 2022.08;

24. Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clin Genitourin Cancer. 2022.08; 20 (4): 276-282.

25. Nguyen MV, Walia A, Saidian A, Puri D, Meagher MF, Hakimi K, Tanaka H, Patil D, Yasuda Y, Saito K, Dhanji S, Cerrato C, Narasimhan R, Perry J, Master V, Fujii Y, Derweesh IH. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma BJU Int. 2022.07;

26. Tanaka H*, Fujii Y. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review Int J Urol. 2022.06;

27. Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation Abdom Radiol (NY) (IF: 3.04; Q2). 2022.06;

28. Meagher MF, Patil D, Saito K, Javier-Desloges JF, Bradshaw AW, Patel SH, Cotta BH, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh IH. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC) Urology. 2022.05; 163 164-176.

29. Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy Urol Oncol (IF: 3.5; Q3). 2022.04;

30. Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma Diagnostics (Basel). 2022.03; 12 (4): 817.

31. Yoshida S, Matsushima H, Fujii Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity World J Urol (IF: 4.23; Q1). 2022.03;

32. Yoshida S, Fujii Y. Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis Int J Urol (IF: 3.37; Q2). 2022.03;

33. Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination Eur J Radiol (IF: 3.53; Q2). 2022.03;

34. Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer Eur Radiol (IF: 5.32; Q1). 2022.02;

35. Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response 2022.01;

36. Cathrine Keiner, Margaret Meagher, Dattatraya Patil, Kazutaka Saito, Arman Walia, Franklin Liu, Raksha Dutt, Nathan Miller, Sohail Dhanji, Ava Saidian, Fang Wan, Yosuke Yasuda, Yasuhisa Fujii, Hajime Tanaka, Viraj Master, Ithaar Derweesh. Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis. Front Oncol. 2022; 12 995991. ( PubMed, DOI )

37. Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Fujiwara M, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy Int J Urol. 2022;

38. Preedanan W, Suzuki K, Kondo T, Kobayashi M, Tanaka H, Ishioka J, Matsuoka Y, Fujii Y, Kumazawa I.. Improvement of Urinary Stone Segmentation Using GAN-Based Urinary Stones Inpainting Augmentation. IEEE Access. 2022;

39. Tanaka H*, Fukuda S, Kimura K, Fukawa Y, Yamamoto K, Fukushima H, Moriyama S, Yasuda Y, Uehara S, Waseda Y, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Tateishi U, Campbell SC, Fujii Y. . Defining tumour shape irregularity for preoperative risk stratification of clinically localised renal cell carcinoma Eur Urol Open Sci. . 2022;

40. Yuan JH, Tanaka H, Patil D, Hakimi K, Soliman S, Meagher M, Saidian A, Walia A, Dhanji S, Liu F, Afari J, Nguyen M, Wang L, Yasuda Y, Saito K, Fujii Y, Master V, Derweesh IH. . Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. Clin Genitourin Cancer. 2022;